16^th Asia Pacific Oncologists Annual Meeting

Benign tumors that are not identified as malignant and the malignant tumor which is identified as cancer must follow two different human physiological and immunological consequences. We all carry cancer cells and or generate cancer cells continuously during our growths and metabolic processes and by environmental impacts, like temperature, humidity, smokes, dust and UV of sunrays. The concept of BNT (Bionanotube of Escherichia coli K-12) is one such concept to optimize the delivery system of chemotherapeutic drugs and to sustain the body immune system/bidirectional immune response (i.e. to kill cancer malignant cells through chemotherapeutic drugs, immobilized in BNT and at the same time helps to normalize the body immune system, since BNT is genetically engineered E. coli cell, there extracted surface antigen fimbriae (pili), are the expressed cloned gene of cancer cell. BNT carrying cancer chemotherapeutic drug immobilized, is specific to the cancer cell and the necessitate body immune response responsible to sustain the body immune response. The main danger in chemotherapy is the damage of patient's immune system during and after administration, responsible to prevent the growth of opportunistic bacterial growths, increasing in case of immune suppression, susceptible to the body. BNT has initiated the concept for anticancer drug from the studies of anti-adherent activities of microbes in Balb/C mice to prevent fatal diarrhea. The immune response in this case was unique to observe the difference in mortality of mice against inoculums of donor fatal diarrhea causing bacteria and a group with BNT injected peritoneal survived against fatal diarrhea causing bacteria infected to mice and increased up to 10 8 ells/0.2 ml.